In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population

Acta Pharmacologica Sinica

Volumn 34, Issue 11, 2013, Pages 1449-1456

  Dai, Da Peng ^a   Wang, Yu Han ^b   Wang, Shuang Hu ^c   Geng, Pei Wu ^c   Hu, Li Ming ^c   Hu, Guo Xin ^c   Cai, Jian Ping ^a  

^a BEIJING HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Allelic variants; Chinese Han population; CYP2C9; Drug metabolism; Tolbutamide

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 2C9; TOLBUTAMIDE;

ALLELE; ALLELIC VARIANT; ANIMAL CELL; ARTICLE; BACULOVIRUS; CELL STRAIN COS7; CHINESE; CHINESE HAN POPULATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXPRESSION VECTOR; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; INSECT CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; MICROSOME; NONHUMAN; PHARMACOGENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ALLELES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; HUMANS; ISOENZYMES; MICROSOMES; SF9 CELLS; SPODOPTERA; TOLBUTAMIDE;

EID: 84887352555     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.123     Document Type: Article

References (27)

1. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20: 277-81.
2. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 2009; 10: 1075-126.
3. Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012; 27: 68-84.
4. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009; 10: 781-834.
5. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012; 27: 9-54.
6. Sanchez-Diz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibanez L, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J 2009; 9: 306-10.
7. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31: 1549-57.
8. Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, et al. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009; 37: 1895-903.
9. Dai DP, Xu RA, Hu LM, Wang SH, Geng PW, Yang JF, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 2013. doi: 10.1038/tpj.2013.2.
10. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9. (Pubitemid 30142817)
11. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-9. (Pubitemid 38971236)
12. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-9. (Pubitemid 39221795)
13. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085-90. (Pubitemid 41635394)
14. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497-514. (Pubitemid 43922347)
15. Xiong Y, Wang M, Fang K, Xing Q, Feng G, Shen L, et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 2011; 97: 277-81.
16. Herman D, Dolzan V, Ingelman-Sundberg M. Characterization of the novel defective CYP2C9 24 allele. Drug Metab Dispos 2007; 35: 831-4. (Pubitemid 46798612)
17. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42. (Pubitemid 24106122)
18. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9. (Pubitemid 26288624)
19. Hanatani T, Fukuda T, Onishi S, Funae Y, Azuma J. No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3. Eur J Clin Pharmacol 2003; 59: 233-5. (Pubitemid 36995132)
20. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104. (Pubitemid 30193071)
21. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H. Catalytic activities of human cytochrome P450 2C9 1, 2C9 3 and 2C9 13. Xenobiotica 2005; 35: 853-61. (Pubitemid 41759171)
22. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418-22.
23. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527-37. (Pubitemid 39106854)
24. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (8) polymorphism. Clin Pharmacol Ther 2012; 91: 660-5.
25. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-86. (Pubitemid 41531727)
26. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353-64. (Pubitemid 40719264)
27. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009; 3: 169-90.